Distribution · Southeast Asia · Announced 21 May 2026
Hanmi Pharmaceutical → Organon
Hanmi Pharmaceutical will supply three cardiovascular and respiratory combination drugs to Organon for Malaysia and the Philippines, in a deal worth about KRW 52.7bn (~US$34M) over ten years.
Parties: Hanmi Pharmaceutical (South Korea) → Organon (United States)
- Deal type
- Distribution
- Value
- $34m
- Territory
- Malaysia, Philippines
- Therapeutic area
- Multi-therapy
- Asset
- Three cardiovascular and respiratory combination products for Malaysia and the Philippines (two already approved in the Philippines)
- Announced
- 21 May 2026
Our analysis
Why this matters
Hanmi Pharmaceutical has signed an export supply agreement with Organon for three combination drugs in cardiovascular and respiratory care, to be sold in Malaysia and the Philippines. Two of the products are already approved in the Philippines. Hanmi puts the deal's value at about KRW 52.7 billion (about US$34 million), based on projected revenue over ten years.
Fixed-dose combinations are one of Korea's strongest pharmaceutical exports: they improve adherence in chronic disease and are hard for local generics makers to copy quickly. For Organon, which needs products for its established-brands business in emerging markets, in-licensing differentiated combinations is cheaper than developing them.
The full analysis is free to read with a work email on this page.
Source: Seoul Economic Daily